U.S. flag

An official website of the United States government

NM_025103.4(IFT74):c.69G>C (p.Arg23Ser) AND not provided

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Feb 28, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003022498.2

Allele description [Variation Report for NM_025103.4(IFT74):c.69G>C (p.Arg23Ser)]

NM_025103.4(IFT74):c.69G>C (p.Arg23Ser)

Gene:
IFT74:intraflagellar transport 74 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
9p21.2
Genomic location:
Preferred name:
NM_025103.4(IFT74):c.69G>C (p.Arg23Ser)
HGVS:
  • NC_000009.12:g.26962036G>C
  • NG_053083.1:g.20047G>C
  • NM_001099222.3:c.69G>C
  • NM_001099223.3:c.69G>C
  • NM_001099224.3:c.69G>C
  • NM_001349928.2:c.69G>C
  • NM_025103.4:c.69G>CMANE SELECT
  • NP_001092692.1:p.Arg23Ser
  • NP_001092693.1:p.Arg23Ser
  • NP_001092694.1:p.Arg23Ser
  • NP_001336857.1:p.Arg23Ser
  • NP_079379.2:p.Arg23Ser
  • NC_000009.11:g.26962034G>C
Protein change:
R23S
Molecular consequence:
  • NM_001099222.3:c.69G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001099223.3:c.69G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001099224.3:c.69G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001349928.2:c.69G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_025103.4:c.69G>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

  • Community Pharmacy Services
    Community Pharmacy Services
    Total pharmaceutical services provided to the public through community pharmacies.<br/>Year introduced: 1968
    MeSH
  • Legislation, Pharmacy
    Legislation, Pharmacy
    Laws and regulations, pertaining to the field of pharmacy, proposed for enactment or enacted by a legislative body.<br/>Year introduced: 1968
    MeSH
  • Genetic Counseling
    Genetic Counseling
    An educational process that provides information and advice to individuals or families about a genetic condition that may affect them. The purpose is to help individuals make ...<br/>Year introduced: 1973
    MeSH

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003318750Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Feb 28, 2022)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV003318750.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This sequence change replaces arginine, which is basic and polar, with serine, which is neutral and polar, at codon 23 of the IFT74 protein (p.Arg23Ser). This variant is present in population databases (rs775728464, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with IFT74-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024